{
  "id": 13901344,
  "title": "Pacira BioSciences SVP Riker sells $217,920 stock",
  "url": "https://urgent.news/2026/10/12/pacira-biosciences-svp-riker-sells-217-920-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T07:31:07.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/pacira-biosciences-svp-riker-sells-217920-stock-93CH-4943386"
  },
  "original_language": "en",
  "account": "Lauren Riker, Senior Vice President of Finance at Pacira BioSciences Inc., sold 6,000 shares of the company's common stock on October 8, 2026. This transaction followed the exercise of stock options valued at $194,100, with shares purchased at $32.35 per share. Immediately after, Riker disposed of the 6,000 shares at $36.32 per share, resulting in a total sale value of $217,920. Pacira's stock had risen nearly 45% over the previous week and was trading near its 52-week high of $36.46. The stock remains undervalued according to its Fair Value estimate, with a further 18 ProTips available to subscribers. Riker's stock options vested 25% of the shares on the grant date's first anniversary, with the remaining shares vesting in quarterly installments over three years. As of the reported transactions, Riker directly holds 62,284.242 shares of Pacira BioSciences common stock. In other news, Pacira reported a 6% increase in second-quarter revenue to $192.4 million, surpassing analysts' expectations of $191.06 million. Viatris announced its acquisition of Pacira Pharmaceuticals for $1.65 billion, prompting Jefferies to downgrade Pacira to \"Hold\" with a price target of $36.00. Oppenheimer initiated coverage with an \"Outperform\" rating and a price target of $32.00, citing Exparel's growing market presence.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}